Letter to the editor: Incidence of de novo malignancy and all-cause mortality among heart transplant recipients

among heart transplant recipients over a span of three decades, with a the increased mortality associated with aggressive cancers such as tation of certain demographic groups limits the applicability of the tween immunosuppressive therapy and cancer risk, it lacks a compredurations, which can significantly influence cancer risk [3,4]. For instance, calcineurin inhibitors (e.g., cyclosporine and tacrolimus), commonly used in transplant regimens, are linked to an increased risk of skin cancers. In contrast, mTOR inhibitors (e.g., sirolimus) may have a different risk profile [5]. What I want to address is the role of immu